TRVI EBITDA
-$51.04MTTM · USD
Period ending:
TRVI FY EBITDAUSD
$0.00-$47.79M
2016-12-312025-12-31
Source: Financial Modeling Prep (FMP). Annual fiscal periods; reported in USD. Dates are period ends; a fiscal year may differ from a calendar year.
TRVI ebitda history
Earnings before interest, taxes, depreciation, and amortization. The available annual fiscal periods series contains 10 observations from Dec 31, 2016 to Dec 31, 2025.
| Period ending | EBITDA (USD) |
|---|---|
| -42,679,000 | |
| -47,790,000 | |
| -28,583,000 | |
| -27,982,000 | |
| -32,709,000 | |
| -32,272,999 | |
| -26,606,000 | |
| -18,385,000 | |
| -8,188,000 | |
| -8,621,000 |
Compare ebitda
Other companies in Health Care. Each page shows its own reporting periods and currency.
- Guardant Health Inc (GH) ebitda
- Bridgebio Pharma Inc (BBIO) ebitda
- Brightspring Health Services Inc (BTSG) ebitda
- Madrigal Pharmaceuticals Inc (MDGL) ebitda
- Ensign Group Inc (ENSG) ebitda
- Glaukos Corp (GKOS) ebitda
- Vaxcyte Inc (PCVX) ebitda
- Krystal Biotech Inc (KRYS) ebitda
All TRVI financial metrics · TRVI stock overview · How to interpret financial metrics
